- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Smilow Cancer Hospital at Waterbury1075 Chase ParkwayWaterbury, CT 06708
- Smilow Cancer HospitalSmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
Elena Ratner, MD, MBA
Biography
Elena Ratner, MD, is a gynecologic oncologist specializing in ovarian malignancies. An advocate for cancer survivors, she is also co-founder and director of the Yale Medicine Sexual, Intimacy and Menopause Program (SIMS), one of the first programs in the country to focus on supporting cancer survivors coping with issues that may not be discussed in the other clinical settings.
More than 22,000 American women are diagnosed with ovarian cancer each year. As a clinician working with these patients, Dr. Ratner stresses the importance of social networks during treatment, and helps facilitate one-on-one mentoring for those currently receiving treatment and those who have completed treatment. “We want these women to receive personal attention from somebody who has gone through this treatment before,” she says. “It is so important for women who need to know that they are not alone in this fight.”
Dr. Ratner is an associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine. Her clinical research focuses on new targeted drugs for ovarian cancer that will provide truly personalized care, and on reversing chemotherapy resistance in ovarian and uterine cancers. She also studies chemotherapy targeted drug development, quality-of-life programs for patients and early cancer detection. Dr. Ratner is a recipient of multiple awards, including the 2015 Yale Cancer Center Award for Clinical Excellence.
Titles
- Professor of Obstetrics, Gynecology & Reproductive Sciences
- Co-Chief, Section of Gynecologic Oncology
Education & Training
- MBAYale University School of Management (2021)
- FellowshipYale University School of Medicine (2010)
- ResidencyYale-New Haven Hospital (2007)
- MDState University of NY Medical College (2003)
- BSBarnard College - Columbia University, Premedical Studies (1998)
- FellowshipYale University - School Of Medicine
Additional Information
- Habib A, Pitafi S, Ratner E, Abramsohn E, Lindau S, Gross C, Schulman-Green D. “Showing some care”: interest-holders’ perspectives on addressing health-related social conditions in ovarian cancer. The Oncologist 2026, 31: oyag077. PMID: 41838415, PMCID: PMC13035072, DOI: 10.1093/oncolo/oyag077.
- Palmieri L, Bellone S, Demirkiran C, Hartwich T, Sethi N, Ettorre V, Ottum S, Greenman M, Buza N, Hui P, Perrone E, Fanfani F, Fagotti A, Ratner E, Santin A. Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. Gynecologic Oncology 2026, 206: 65-73. PMID: 41690203, DOI: 10.1016/j.ygyno.2026.02.004.
- Hartwich T, Choi S, Hwang A, Bellone S, Palmieri L, Seo H, Kim T, Hong J, Krakstad C, Trovik J, Stefansson I, Haugland H, Greenman M, Ettorre V, Ottum S, Demirkiran C, Yang-Hartwich Y, Buza N, Hui P, Lopez S, Cormio G, Ramunno M, Zito A, Perrone E, Fagotti A, Fanfani F, Santoro A, Ravaggi A, Bignotti E, Odicino F, Ardighieri L, Ratner E, Angioli R, Perrone G, Luvero D, Conca B, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of endometrial stromal sarcoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2531105123. PMID: 41591910, PMCID: PMC12867622, DOI: 10.1073/pnas.2531105123.
- Cao A, Cartmel B, Ratner E, Li F, Schlumbrecht M, Kumar A, Crane T, Esserman D, Irwin M, Ferrucci L. Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer. JNCI Cancer Spectrum 2025, 10: pkaf121. PMID: 41442446, PMCID: PMC12854082, DOI: 10.1093/jncics/pkaf121.
- Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study. International Journal Of Gynecological Cancer 2025, 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.
- Greenman M, Abozenah Y, Pan Y, Ratner E, Altwerger G. HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction. Gynecologic Oncology Reports 2025, 62: 101983. PMID: 41282279, PMCID: PMC12639253, DOI: 10.1016/j.gore.2025.101983.
- Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.
- Amraei R, Niu N, Clark M, Ratner E, Buza N, Hui P. STR genotyping diagnosis of hydatidiform moles: an assessment of 2871 consecutive products of conceptions. Virchows Archiv 2025, 487: 1025-1034. PMID: 41076484, DOI: 10.1007/s00428-025-04282-4.
- Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.
- Fera E, Zhang T, Ratner E, Lin Z. Upregulation of KLF4-NR4A1 signaling reduces poly (ADP-ribose) polymerase inhibitor-induced apoptosis in BRCA2-mutated epithelial ovarian cancer cells. Gynecologic Oncology 2025, 200: 205-206. DOI: 10.1016/j.ygyno.2025.04.266.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. Epithelial ovarian cancer perpetuates immunosuppression by upregulating regulatory T cells and adenosine signaling. Gynecologic Oncology 2025, 200: 206-207. DOI: 10.1016/j.ygyno.2025.04.267.
- Kuroki L, Enserro D, Lankes H, Strickland K, Previs R, Powell M, Klopp A, Ratner E, DiSilvestro P, Cosgrove C, Cantuaria G, Spirtos N, Carney M, Edelson M, Konecny G, Anderson P, Tarney C, Erickson B, Newton M, Tewari K, Thaker P, Warshal D, Armstrong A, Zhou X, Secord A. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249. Gynecologic Oncology 2025, 200: 31-32. DOI: 10.1016/j.ygyno.2025.03.094.
- Ma M, Grechukhina V, Foster M, Lin Z, Ratner E. KMT2C and KMT2D regulate homologous recombination repair and poly (ADP-ribose) polymerase inhibitor sensitivity in epithelial ovarian cancer. Gynecologic Oncology 2025, 200: 319. DOI: 10.1016/j.ygyno.2025.04.454.
- Abozenah Y, Dzienny A, Yamartino K, Pan E, Vlamis C, Azodi M, Ratner E, Santin A, Clark M, Papatla K, Schwartz P, Altwerger G. Retrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose. Gynecologic Oncology 2025, 200: 202. DOI: 10.1016/j.ygyno.2025.04.260.
- Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.
- Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.
- Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.
- Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. Correction: CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer. Scientific Reports 2025, 15: 26787. PMID: 40702101, PMCID: PMC12287456, DOI: 10.1038/s41598-025-12693-1.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer. Scientific Reports 2025, 15: 20778. PMID: 40596479, PMCID: PMC12217468, DOI: 10.1038/s41598-025-06812-1.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.
- Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.
- Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.
- Habib A, Pitafi S, Ratner E, Lindau S, Gross C, Schulman–Green D. “Cancer Will Make You Bankrupt!”– Stakeholders perspectives on managing health–related social needs in ovarian cancer. Health Services Research 2025, 60 PMCID: PMC11972766, DOI: 10.1111/1475-6773.14529.
- AlAshqar A, Maruthi V, Abi-Raad R, Greenman M, Hui P, Ratner E, Altwerger G, Santin A, Andikyan V. Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecologic Oncology Reports 2024, 56: 101652. PMID: 39698441, PMCID: PMC11652878, DOI: 10.1016/j.gore.2024.101652.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, Martin L, Matei D, Miller D, Robertson S, Barroilhet L, Uppal S, Hendrickson A, Gershenson D, Gray H, Hakam A, Jain A, Konecny G, Moroney J, Ratner E, Schorge J, Thaker P, Werner T, Zsiros E, Behbakht K, Chen L, DeRosa M, Eisenhauer E, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez R, Armstrong D. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 512-519. PMID: 39413835, DOI: 10.6004/jnccn.2024.0052.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024, 44: 144-154. PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.
- Erickson B, Enserro D, Lankes H, Dockery L, ghamande S, Oliver M, Gressel G, Castellano T, Ratner E, Deery A, Bishop E, Bradford L, Thomes Pepin J, Burton E, Blank S, Santin A, Havrilesky L, Aghajanian C, Nickles Fader A, Powell M. Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Journal Of Clinical Oncology 2024, 42: tps5641-tps5641. DOI: 10.1200/jco.2024.42.16_suppl.tps5641.
- Liu J, Gaillard S, Hendrickson A, Yeku O, Diver E, Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang H, Compton N, Baines A, Bacqué E, Liu X, Felicetti B, Konecny G. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology 2024, 8: e2300693. PMID: 38754056, PMCID: PMC11371093, DOI: 10.1200/po.23.00693.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Nagy A, Niu N, Ratner E, Hui P, Buza N. Novel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications. International Journal Of Gynecological Pathology 2024, 43: 631-636. PMID: 38426544, DOI: 10.1097/pgp.0000000000001024.
- Thomson C, Crane T, Miller A, Gold M, Powell M, Bixel K, Van Le L, DiSilvestro P, Ratner E, Lele S, Guntupalli S, Huh W, Robertson S, Modesitt S, Casey A, Basen-Engquist K, Skiba M, Walker J, Kachnic L, Alberts D. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors. Gynecologic Oncology 2023, 170: 11-18. PMID: 36608382, PMCID: PMC10023359, DOI: 10.1016/j.ygyno.2022.12.017.
- Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, Chen L, Cristea M, DeRosa M, Eisenhauer E, Gershenson D, Gray H, Grisham R, Hakam A, Jain A, Karam A, Konecny G, Leath C, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller D, O'Malley D, Percac-Lima S, Ratner E, Remmenga S, Vargas R, Werner T, Zsiros E, Burns J, Engh A. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 191-226. PMID: 33545690, DOI: 10.6004/jnccn.2021.0007.
- Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, Berek J, Chen L, Cristea M, DeRosa M, ElNaggar A, Gershenson D, Gray H, Hakam A, Jain A, Johnston C, Leath C, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley D, Penson R, Percac-Lima S, Ratner E, Remmenga S, Sabbatini P, Werner T, Zsiros E, Burns J, Engh A. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 896-909. PMID: 31390583, DOI: 10.6004/jnccn.2019.0039.
- Gastrointestinal (GI) & Pancreatic Cancer Prevention Program
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Minimally Invasive Surgical Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Ovarian Cancer Early Detection Program
- Smilow Sexuality, Intimacy & Menopause Program
- Yale Cancer Center
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Smilow Cancer Hospital at Waterbury1075 Chase ParkwayWaterbury, CT 06708
- Smilow Cancer HospitalSmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
Biography
Elena Ratner, MD, is a gynecologic oncologist specializing in ovarian malignancies. An advocate for cancer survivors, she is also co-founder and director of the Yale Medicine Sexual, Intimacy and Menopause Program (SIMS), one of the first programs in the country to focus on supporting cancer survivors coping with issues that may not be discussed in the other clinical settings.
More than 22,000 American women are diagnosed with ovarian cancer each year. As a clinician working with these patients, Dr. Ratner stresses the importance of social networks during treatment, and helps facilitate one-on-one mentoring for those currently receiving treatment and those who have completed treatment. “We want these women to receive personal attention from somebody who has gone through this treatment before,” she says. “It is so important for women who need to know that they are not alone in this fight.”
Dr. Ratner is an associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine. Her clinical research focuses on new targeted drugs for ovarian cancer that will provide truly personalized care, and on reversing chemotherapy resistance in ovarian and uterine cancers. She also studies chemotherapy targeted drug development, quality-of-life programs for patients and early cancer detection. Dr. Ratner is a recipient of multiple awards, including the 2015 Yale Cancer Center Award for Clinical Excellence.
Titles
- Professor of Obstetrics, Gynecology & Reproductive Sciences
- Co-Chief, Section of Gynecologic Oncology
Education & Training
- MBAYale University School of Management (2021)
- FellowshipYale University School of Medicine (2010)
- ResidencyYale-New Haven Hospital (2007)
- MDState University of NY Medical College (2003)
- BSBarnard College - Columbia University, Premedical Studies (1998)
- FellowshipYale University - School Of Medicine
Additional Information
- Habib A, Pitafi S, Ratner E, Abramsohn E, Lindau S, Gross C, Schulman-Green D. “Showing some care”: interest-holders’ perspectives on addressing health-related social conditions in ovarian cancer. The Oncologist 2026, 31: oyag077. PMID: 41838415, PMCID: PMC13035072, DOI: 10.1093/oncolo/oyag077.
- Palmieri L, Bellone S, Demirkiran C, Hartwich T, Sethi N, Ettorre V, Ottum S, Greenman M, Buza N, Hui P, Perrone E, Fanfani F, Fagotti A, Ratner E, Santin A. Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. Gynecologic Oncology 2026, 206: 65-73. PMID: 41690203, DOI: 10.1016/j.ygyno.2026.02.004.
- Hartwich T, Choi S, Hwang A, Bellone S, Palmieri L, Seo H, Kim T, Hong J, Krakstad C, Trovik J, Stefansson I, Haugland H, Greenman M, Ettorre V, Ottum S, Demirkiran C, Yang-Hartwich Y, Buza N, Hui P, Lopez S, Cormio G, Ramunno M, Zito A, Perrone E, Fagotti A, Fanfani F, Santoro A, Ravaggi A, Bignotti E, Odicino F, Ardighieri L, Ratner E, Angioli R, Perrone G, Luvero D, Conca B, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of endometrial stromal sarcoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2531105123. PMID: 41591910, PMCID: PMC12867622, DOI: 10.1073/pnas.2531105123.
- Cao A, Cartmel B, Ratner E, Li F, Schlumbrecht M, Kumar A, Crane T, Esserman D, Irwin M, Ferrucci L. Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer. JNCI Cancer Spectrum 2025, 10: pkaf121. PMID: 41442446, PMCID: PMC12854082, DOI: 10.1093/jncics/pkaf121.
- Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study. International Journal Of Gynecological Cancer 2025, 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.
- Greenman M, Abozenah Y, Pan Y, Ratner E, Altwerger G. HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction. Gynecologic Oncology Reports 2025, 62: 101983. PMID: 41282279, PMCID: PMC12639253, DOI: 10.1016/j.gore.2025.101983.
- Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.
- Amraei R, Niu N, Clark M, Ratner E, Buza N, Hui P. STR genotyping diagnosis of hydatidiform moles: an assessment of 2871 consecutive products of conceptions. Virchows Archiv 2025, 487: 1025-1034. PMID: 41076484, DOI: 10.1007/s00428-025-04282-4.
- Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.
- Fera E, Zhang T, Ratner E, Lin Z. Upregulation of KLF4-NR4A1 signaling reduces poly (ADP-ribose) polymerase inhibitor-induced apoptosis in BRCA2-mutated epithelial ovarian cancer cells. Gynecologic Oncology 2025, 200: 205-206. DOI: 10.1016/j.ygyno.2025.04.266.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. Epithelial ovarian cancer perpetuates immunosuppression by upregulating regulatory T cells and adenosine signaling. Gynecologic Oncology 2025, 200: 206-207. DOI: 10.1016/j.ygyno.2025.04.267.
- Kuroki L, Enserro D, Lankes H, Strickland K, Previs R, Powell M, Klopp A, Ratner E, DiSilvestro P, Cosgrove C, Cantuaria G, Spirtos N, Carney M, Edelson M, Konecny G, Anderson P, Tarney C, Erickson B, Newton M, Tewari K, Thaker P, Warshal D, Armstrong A, Zhou X, Secord A. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249. Gynecologic Oncology 2025, 200: 31-32. DOI: 10.1016/j.ygyno.2025.03.094.
- Ma M, Grechukhina V, Foster M, Lin Z, Ratner E. KMT2C and KMT2D regulate homologous recombination repair and poly (ADP-ribose) polymerase inhibitor sensitivity in epithelial ovarian cancer. Gynecologic Oncology 2025, 200: 319. DOI: 10.1016/j.ygyno.2025.04.454.
- Abozenah Y, Dzienny A, Yamartino K, Pan E, Vlamis C, Azodi M, Ratner E, Santin A, Clark M, Papatla K, Schwartz P, Altwerger G. Retrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose. Gynecologic Oncology 2025, 200: 202. DOI: 10.1016/j.ygyno.2025.04.260.
- Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.
- Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.
- Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.
- Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. Correction: CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer. Scientific Reports 2025, 15: 26787. PMID: 40702101, PMCID: PMC12287456, DOI: 10.1038/s41598-025-12693-1.
- Lin A, Moscarelli J, Zhu Y, Lin Z, Ratner E. CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer. Scientific Reports 2025, 15: 20778. PMID: 40596479, PMCID: PMC12217468, DOI: 10.1038/s41598-025-06812-1.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.
- Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.
- Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.
- Habib A, Pitafi S, Ratner E, Lindau S, Gross C, Schulman–Green D. “Cancer Will Make You Bankrupt!”– Stakeholders perspectives on managing health–related social needs in ovarian cancer. Health Services Research 2025, 60 PMCID: PMC11972766, DOI: 10.1111/1475-6773.14529.
- AlAshqar A, Maruthi V, Abi-Raad R, Greenman M, Hui P, Ratner E, Altwerger G, Santin A, Andikyan V. Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecologic Oncology Reports 2024, 56: 101652. PMID: 39698441, PMCID: PMC11652878, DOI: 10.1016/j.gore.2024.101652.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, Martin L, Matei D, Miller D, Robertson S, Barroilhet L, Uppal S, Hendrickson A, Gershenson D, Gray H, Hakam A, Jain A, Konecny G, Moroney J, Ratner E, Schorge J, Thaker P, Werner T, Zsiros E, Behbakht K, Chen L, DeRosa M, Eisenhauer E, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez R, Armstrong D. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 512-519. PMID: 39413835, DOI: 10.6004/jnccn.2024.0052.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.
- Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024, 44: 144-154. PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.
- Erickson B, Enserro D, Lankes H, Dockery L, ghamande S, Oliver M, Gressel G, Castellano T, Ratner E, Deery A, Bishop E, Bradford L, Thomes Pepin J, Burton E, Blank S, Santin A, Havrilesky L, Aghajanian C, Nickles Fader A, Powell M. Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Journal Of Clinical Oncology 2024, 42: tps5641-tps5641. DOI: 10.1200/jco.2024.42.16_suppl.tps5641.
- Liu J, Gaillard S, Hendrickson A, Yeku O, Diver E, Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang H, Compton N, Baines A, Bacqué E, Liu X, Felicetti B, Konecny G. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology 2024, 8: e2300693. PMID: 38754056, PMCID: PMC11371093, DOI: 10.1200/po.23.00693.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.
- Nagy A, Niu N, Ratner E, Hui P, Buza N. Novel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications. International Journal Of Gynecological Pathology 2024, 43: 631-636. PMID: 38426544, DOI: 10.1097/pgp.0000000000001024.
- Thomson C, Crane T, Miller A, Gold M, Powell M, Bixel K, Van Le L, DiSilvestro P, Ratner E, Lele S, Guntupalli S, Huh W, Robertson S, Modesitt S, Casey A, Basen-Engquist K, Skiba M, Walker J, Kachnic L, Alberts D. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors. Gynecologic Oncology 2023, 170: 11-18. PMID: 36608382, PMCID: PMC10023359, DOI: 10.1016/j.ygyno.2022.12.017.
- Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, Chen L, Cristea M, DeRosa M, Eisenhauer E, Gershenson D, Gray H, Grisham R, Hakam A, Jain A, Karam A, Konecny G, Leath C, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller D, O'Malley D, Percac-Lima S, Ratner E, Remmenga S, Vargas R, Werner T, Zsiros E, Burns J, Engh A. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 191-226. PMID: 33545690, DOI: 10.6004/jnccn.2021.0007.
- Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, Berek J, Chen L, Cristea M, DeRosa M, ElNaggar A, Gershenson D, Gray H, Hakam A, Jain A, Johnston C, Leath C, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley D, Penson R, Percac-Lima S, Ratner E, Remmenga S, Sabbatini P, Werner T, Zsiros E, Burns J, Engh A. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 896-909. PMID: 31390583, DOI: 10.6004/jnccn.2019.0039.
- Gastrointestinal (GI) & Pancreatic Cancer Prevention Program
- Gynecologic Oncology Program
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Minimally Invasive Surgical Program
- Obstetrics, Gynecology & Reproductive Sciences
- Oligometastatic Cancer Program
- Ovarian Cancer Early Detection Program
- Smilow Sexuality, Intimacy & Menopause Program
- Yale Cancer Center
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Smilow Cancer Hospital at Waterbury1075 Chase ParkwayWaterbury, CT 06708
- Smilow Cancer HospitalSmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385
- Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven35 Park Street, Wing North Pavilion 1, suite BNew Haven, CT 06511
- Smilow Cancer Hospital at Waterbury1075 Chase ParkwayWaterbury, CT 06708
- Smilow Cancer HospitalSmilow Cancer Hospital at Waterford230 Waterford Parkway SouthWaterford, CT 06385